NEW TECH FOODS

Symrise has announced a strategic equity investment in Cellibre, a US-based biotechnology company focused on sustainable biomanufacturing.

Founded in 2017, Cellibre engineers microorganisms to produce cultured natural products and specialuty chemicals used across pharmaceuticals, beauty and functional health sectors.

The partnership aims to accelerate Symrise’s innovation in fermentation-derived ingredients for use in taste solutions, cosmetics and other applications.

Through the investment, Symrise will gain preferred access to Cellibre’s proprietary fermentation platform, designed to enable scalable and consistent production of high-value ingredients across the food, beverage, cosmetic and nutraceutical industries.

The collaboration is expected to strengthen supply chain resilience and reduce reliance on seasonal or agricultural sourcing.

Imke Meyer, project lead for biotechnology at Symrise, said: "This investment accelerates our biotechnology roadmap and strengthens our ability to deliver sustainable, high-quality solutions to our customers. Together with Cellibre, we will combine scientific expertise with application know-how and market reach to unlock new growth opportunities."

Ben Chiarelli, CEO of Cellibre, said: "Since 2017, we have been led by the belief that biology is the future of manufacturing and we are committed to creating more resilient supply chains, delivering products that are lower cost and higher quality while limiting the impact on natural ecosystems".

"This partnership represents another external validation of our approach, technology and team, and will leverage the Symrise team’s global market access and deep expertise in flavours, fragrances and cosmetics – creating powerful synergies for both companies."